Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 ...

On August 5, 2025, investors in Hims & Hers Health (NYSE: HIMS) declined almost 11% in another sell-off after the company disclosed ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...